Wescott Financial Advisory Group’s eFFECTOR Therapeutics, Inc. Common Stock EFTR Stock Holding History

Wescott Financial Advisory Group’s Portfolio EFTR Stock Details EFTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-1,222	Closed	-$14.3K	–	174
2023 Q4	$14.3K	Hold	1,222	–	–	﹤0.01%	164
2023 Q3	$18.3K	Hold	1,222	–	–	﹤0.01%	157
2023 Q2	$25.4K	Hold	1,222	–	–	﹤0.01%	160
2023 Q1	$10.8K	Sell	1,222 -400	-25%	-$4.85K	﹤0.01%	156
2022 Q4	$17.3K	Sell	1,622 -600	-27%	-$7.61K	﹤0.01%	156
2022 Q3	$32K	Buy	+2,222	New	+$43.5K	0.01%	136

Other funds holding EFTR

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return

Stempoint Capital New York $522M AUM 281.95% 1-Year Est. Return

SAM

Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return

Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

RJA

Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

Wescott Financial Advisory Group's EFTR Position: Q1 2024 in Review

Wescott Financial Advisory Group sold out of eFFECTOR Therapeutics, Inc. Common Stock (EFTR) in Q1 2024, closing a stake of 1,222 shares — an estimated $14.3K sold.

Wescott Financial Advisory Group first reported a position in EFTR in Q3 2022 and held it in 6 quarters. The position peaked at $32K in Q3 2022. 17 funds tracked by Wall St. Rank hold EFTR as of Q1 2024.

Wescott Financial Advisory Group reported no remaining eFFECTOR Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
Wescott Financial Advisory Group sold 1,222 eFFECTOR Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $14.3K.
Wescott Financial Advisory Group first reported a position in eFFECTOR Therapeutics, Inc. Common Stock in Q3 2022 and held it in 6 quarters.
Wescott Financial Advisory Group's eFFECTOR Therapeutics, Inc. Common Stock position peaked at $32K in Q3 2022.
17 funds tracked by Wall St. Rank held eFFECTOR Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Wescott Financial Advisory Group's 13F filing for Q1 2024, filed 13 May 2024.